Annual EBITDA
-$35.21 M
+$24.86 M+41.39%
December 31, 2023
Summary
- As of February 12, 2025, ALDX annual EBITDA is -$35.21 million, with the most recent change of +$24.86 million (+41.39%) on December 31, 2023.
- During the last 3 years, ALDX annual EBITDA has risen by +$864.30 thousand (+2.40%).
- ALDX annual EBITDA is now -366.33% below its all-time high of $13.22 million, reached on December 31, 2013.
Performance
ALDX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$14.57 M
+$1.74 M+10.65%
September 30, 2024
Summary
- As of February 12, 2025, ALDX quarterly EBITDA is -$14.57 million, with the most recent change of +$1.74 million (+10.65%) on September 30, 2024.
- Over the past year, ALDX quarterly EBITDA has dropped by -$6.99 million (-92.15%).
- ALDX quarterly EBITDA is now -254.85% below its all-time high of $9.41 million, reached on December 31, 2013.
Performance
ALDX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$42.57 M
-$6.99 M-19.64%
September 30, 2024
Summary
- As of February 12, 2025, ALDX TTM EBITDA is -$42.57 million, with the most recent change of -$6.99 million (-19.64%) on September 30, 2024.
- Over the past year, ALDX TTM EBITDA has increased by +$836.50 thousand (+1.93%).
- ALDX TTM EBITDA is now -334.32% below its all-time high of $18.17 million, reached on June 30, 2014.
Performance
ALDX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ALDX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +41.4% | -92.2% | +1.9% |
| 3 y3 years | +2.4% | +4.8% | +17.8% |
| 5 y5 years | +9.0% | +21.9% | +30.7% |
ALDX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +41.4% | -249.2% | +15.8% | -53.8% | +33.7% |
| 5 y | 5-year | at high | +42.7% | -249.2% | +15.8% | -53.8% | +33.7% |
| alltime | all time | -366.3% | +42.7% | -254.8% | +33.0% | -334.3% | +33.7% |
Aldeyra Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$14.57 M(-10.7%) | -$42.57 M(+19.6%) |
| Jun 2024 | - | -$16.31 M(+116.8%) | -$35.59 M(+28.6%) |
| Mar 2024 | - | -$7.52 M(+80.3%) | -$27.67 M(-21.4%) |
| Dec 2023 | -$35.21 M(-41.4%) | -$4.17 M(-45.0%) | -$35.21 M(-18.9%) |
| Sep 2023 | - | -$7.58 M(-9.7%) | -$43.41 M(-13.0%) |
| Jun 2023 | - | -$8.40 M(-44.2%) | -$49.90 M(-15.2%) |
| Mar 2023 | - | -$15.06 M(+21.7%) | -$58.81 M(-2.1%) |
| Dec 2022 | -$60.07 M(+7.7%) | -$12.37 M(-12.1%) | -$60.07 M(-4.6%) |
| Sep 2022 | - | -$14.07 M(-18.7%) | -$62.98 M(-1.9%) |
| Jun 2022 | - | -$17.31 M(+6.0%) | -$64.22 M(+4.7%) |
| Mar 2022 | - | -$16.32 M(+6.8%) | -$61.35 M(+10.0%) |
| Dec 2021 | -$55.77 M(+54.6%) | -$15.28 M(-0.2%) | -$55.77 M(+7.7%) |
| Sep 2021 | - | -$15.31 M(+6.1%) | -$51.77 M(+15.6%) |
| Jun 2021 | - | -$14.44 M(+34.4%) | -$44.77 M(+20.0%) |
| Mar 2021 | - | -$10.74 M(-4.8%) | -$37.29 M(+3.9%) |
| Dec 2020 | -$36.07 M(-41.3%) | -$11.28 M(+35.8%) | -$35.91 M(-3.5%) |
| Sep 2020 | - | -$8.31 M(+19.4%) | -$37.22 M(-21.8%) |
| Jun 2020 | - | -$6.96 M(-25.6%) | -$47.57 M(-11.7%) |
| Mar 2020 | - | -$9.36 M(-25.7%) | -$53.89 M(-12.3%) |
| Dec 2019 | -$61.44 M(+58.9%) | -$12.59 M(-32.5%) | -$61.44 M(+3.4%) |
| Sep 2019 | - | -$18.66 M(+40.6%) | -$59.39 M(+15.3%) |
| Jun 2019 | - | -$13.27 M(-21.5%) | -$51.49 M(+9.0%) |
| Mar 2019 | - | -$16.91 M(+60.3%) | -$47.23 M(+22.1%) |
| Dec 2018 | -$38.68 M | -$10.55 M(-2.0%) | -$38.68 M(+10.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$10.76 M(+19.5%) | -$35.04 M(+19.9%) |
| Jun 2018 | - | -$9.01 M(+7.8%) | -$29.23 M(+14.6%) |
| Mar 2018 | - | -$8.36 M(+20.9%) | -$25.49 M(+14.9%) |
| Dec 2017 | -$22.19 M(+19.6%) | -$6.91 M(+39.7%) | -$22.19 M(+11.6%) |
| Sep 2017 | - | -$4.95 M(-6.1%) | -$19.89 M(+1.1%) |
| Jun 2017 | - | -$5.27 M(+4.3%) | -$19.68 M(+5.4%) |
| Mar 2017 | - | -$5.05 M(+9.5%) | -$18.68 M(+0.6%) |
| Dec 2016 | -$18.56 M(+55.2%) | -$4.62 M(-2.6%) | -$18.56 M(+1.6%) |
| Sep 2016 | - | -$4.74 M(+11.1%) | -$18.26 M(+8.4%) |
| Jun 2016 | - | -$4.27 M(-13.5%) | -$16.85 M(+14.0%) |
| Mar 2016 | - | -$4.93 M(+14.2%) | -$14.79 M(+23.6%) |
| Dec 2015 | -$11.96 M(+142.0%) | -$4.32 M(+29.7%) | -$11.96 M(+19.0%) |
| Sep 2015 | - | -$3.33 M(+51.3%) | -$10.05 M(+15.7%) |
| Jun 2015 | - | -$2.20 M(+4.5%) | -$8.69 M(+14.8%) |
| Mar 2015 | - | -$2.11 M(-12.6%) | -$7.56 M(+53.1%) |
| Dec 2014 | -$4.94 M(-137.4%) | -$2.41 M(+22.5%) | -$4.94 M(-171.9%) |
| Sep 2014 | - | -$1.97 M(+82.4%) | $6.88 M(-62.1%) |
| Jun 2014 | - | -$1.08 M(-309.5%) | $18.17 M(+2.7%) |
| Mar 2014 | - | $515.00 K(-94.5%) | $17.69 M(+33.8%) |
| Dec 2013 | $13.22 M(-158.2%) | $9.41 M(+0.9%) | $13.22 M(-173.8%) |
| Sep 2013 | - | $9.32 M(-700.2%) | -$17.92 M(-34.2%) |
| Jun 2013 | - | -$1.55 M(-60.8%) | -$27.24 M(+6.0%) |
| Mar 2013 | - | -$3.96 M(-81.8%) | -$25.69 M(+18.2%) |
| Dec 2012 | -$22.73 M(+984.1%) | -$21.73 M | -$21.73 M |
| Dec 2011 | -$2.10 M | - | - |
FAQ
- What is Aldeyra Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Aldeyra Therapeutics?
- What is Aldeyra Therapeutics annual EBITDA year-on-year change?
- What is Aldeyra Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Aldeyra Therapeutics?
- What is Aldeyra Therapeutics quarterly EBITDA year-on-year change?
- What is Aldeyra Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Aldeyra Therapeutics?
- What is Aldeyra Therapeutics TTM EBITDA year-on-year change?
What is Aldeyra Therapeutics annual EBITDA?
The current annual EBITDA of ALDX is -$35.21 M
What is the all time high annual EBITDA for Aldeyra Therapeutics?
Aldeyra Therapeutics all-time high annual EBITDA is $13.22 M
What is Aldeyra Therapeutics annual EBITDA year-on-year change?
Over the past year, ALDX annual EBITDA has changed by +$24.86 M (+41.39%)
What is Aldeyra Therapeutics quarterly EBITDA?
The current quarterly EBITDA of ALDX is -$14.57 M
What is the all time high quarterly EBITDA for Aldeyra Therapeutics?
Aldeyra Therapeutics all-time high quarterly EBITDA is $9.41 M
What is Aldeyra Therapeutics quarterly EBITDA year-on-year change?
Over the past year, ALDX quarterly EBITDA has changed by -$6.99 M (-92.15%)
What is Aldeyra Therapeutics TTM EBITDA?
The current TTM EBITDA of ALDX is -$42.57 M
What is the all time high TTM EBITDA for Aldeyra Therapeutics?
Aldeyra Therapeutics all-time high TTM EBITDA is $18.17 M
What is Aldeyra Therapeutics TTM EBITDA year-on-year change?
Over the past year, ALDX TTM EBITDA has changed by +$836.50 K (+1.93%)